Get the Stockscreener App
324.34
3.38%
-11.33
After Hours:
324.10
-0.24
-0.07%
Beone Medicines Ltd Adr stock is traded at $324.34, with a volume of 274.54K.
It is down -3.38% in the last 24 hours and up +12.58% over the past month.
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.
See More
Previous Close:
$335.67
Open:
$331.66
24h Volume:
274.54K
Relative Volume:
0.70
Market Cap:
$35.55B
Revenue:
$3.81B
Net Income/Loss:
$-644.79M
P/E Ratio:
-51.98
EPS:
-6.24
Net Cash Flow:
$-669.77M
1W Performance:
-5.11%
1M Performance:
+12.58%
6M Performance:
+29.82%
1Y Performance:
+0.00%
1-Day Range:
$324.03
$333.03
1-Week Range:
$312.28
$351.27
52-Week Range:
$172.67
$351.27
Beone Medicines Ltd Adr Stock (ONC) Company Profile
Name
Beone Medicines Ltd Adr
Sector
Industry
Phone
41-616851900
Address
C/O BEONE MEDICINES I GMBH, BASEL
Compare ONC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
Beone Medicines Ltd Adr Stock (ONC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Mar-03-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-03-24 | Resumed | Morgan Stanley | Overweight |
| Sep-18-24 | Initiated | JMP Securities | Mkt Outperform |
| Feb-06-24 | Resumed | JP Morgan | Overweight |
| Sep-12-23 | Initiated | Macquarie | Outperform |
| Aug-17-23 | Initiated | Jefferies | Buy |
| Jul-17-23 | Initiated | Citigroup | Buy |
| Jun-30-23 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-12-23 | Initiated | Daiwa Securities | Buy |
| Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-13-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Aug-09-22 | Resumed | JP Morgan | Overweight |
| Mar-17-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-07-22 | Initiated | Deutsche Bank | Buy |
| Oct-12-21 | Initiated | Bernstein | Outperform |
| Oct-06-21 | Upgrade | CLSA | Underperform → Buy |
| Mar-08-21 | Initiated | China Renaissance | Buy |
| Mar-01-21 | Downgrade | CLSA | Outperform → Underperform |
| Nov-09-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-06-20 | Downgrade | Maxim Group | Buy → Hold |
| Nov-06-20 | Downgrade | Piper Sandler | Neutral → Underweight |
View All
Beone Medicines Ltd Adr Stock (ONC) Latest News
BeOne Medicines (NASDAQ:ONC) Shares Gap Down on Insider Selling - MarketBeat
BeOne Medicines (NASDAQ:ONC) Director Sells $898,105.00 in Stock - MarketBeat
BeOne Medicines (NASDAQ:ONC) Reaches New 12-Month HighStill a Buy? - MarketBeat
BeOne Medicines (NASDAQ:ONC) Sets New 1-Year HighWhat's Next? - MarketBeat
BeOne Medicines (NASDAQ:ONC) Shares Gap UpWhat's Next? - MarketBeat
BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) Receives $330.89 Consensus PT from Brokerages - MarketBeat
Brokerages Set BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) PT at $330.89 - MarketBeat
BeOne Medicines (NASDAQ:ONC) Shares Gap Up – Here’s What Happened - Defense World
BeOne Medicines Stock Gains Momentum With Early-Stage Trial Success For Pretreated Lymphoma Patients - Benzinga
Invesco Ltd. Has $6.89 Million Holdings in Bloomin’ Brands, Inc. $BLMN - Defense World
Invesco Ltd. Sells 206,195 Shares of Brookdale Senior Living Inc. $BKD - Defense World
BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Average Rating of “Buy” from Analysts - Defense World
BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Average Recommendation of “Buy” from Analysts - Defense World
Insider Selling: BeOne Medicines (NASDAQ:ONC) SVP Sells 11,013 Shares of Stock - MarketBeat
BeOne Medicines (NASDAQ:ONC) COO Xiaobin Wu Sells 39,936 Shares - MarketBeat
Insider Selling: BeOne Medicines (NASDAQ:ONC) COO Sells 49,858 Shares of Stock - MarketBeat
BeOne Medicines (NASDAQ:ONC) Sets New 52-Week HighShould You Buy? - MarketBeat
BeOne Medicines (NASDAQ:ONC) Hits New 1-Year High – What’s Next? - Defense World
BeOne Medicines (NASDAQ:ONC) Shares Gap DownShould You Sell? - MarketBeat
BeOne Medicines (NASDAQ:ONC) Sets New 12-Month HighWhat's Next? - MarketBeat
BeOne Medicines DRC earnings missed by $0.04, revenue topped estimates - Investing.com India
Analysts Set BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) PT at $327.56 - Defense World
Chan Henry Lee Sells 920 Shares of BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) Stock - MarketBeat
Insider Selling: BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) Insider Sells 259 Shares of Stock - MarketBeat
BeOne Medicines stock hits 52-week high at 304.0 USD - Investing.com India
Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End - Ariva
BeOne Medicines stock rises after positive EU opinion for lung cancer drug - Investing.com India
Lai Wang Sells 700 Shares of BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) Stock - MarketBeat
Stevanato (STVN) Soars 10.0%: Is Further Upside Left in the Stock? - Yahoo Finance
Beone Medicines Ltd Adr Stock (ONC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.10%
0.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):